A five-year analysis of Singapore Shipping Corporation reveals flat returns on capital, raising questions about its growth trajectory in a competitive maritime sector.
A significant purchase of the VictoryShares USAA Core Short-Term Bond ETF (USTB) by wealth manager Merit Financial Group highlights institutional interest in short-duration, income-focused strategies amid market uncertainty.
A federal lawsuit alleging discriminatory hiring quotas and executive pay tied to demographic targets has placed Comerica's DEI governance under intense scrutiny. The legal challenge emerges as the regional bank navigates its planned acquisition by Fifth Third Bancorp, raising questions about regulatory hurdles and integration risks.
Texas Instruments (TXN) reported a 70% year-over-year surge in data center orders, prompting the company to break out the segment separately. Management forecasts the first sequential revenue growth since 2008, citing improving industrial trends and AI-related infrastructure spending.
While Insas Berhad's (KLSE:INSAS) share price has underperformed the broader market over three years, its total shareholder return tells a different story. A closer look reveals a disconnect between stock performance and underlying business fundamentals, prompting investor scrutiny.
Argentina has reportedly purchased $808 million in Special Drawing Rights from the U.S. Treasury to cover an upcoming interest payment to the International Monetary Fund, highlighting the nation's ongoing financial pressures.
The European Central Bank convenes this week with a resurgent euro presenting a fresh dilemma, threatening to dampen inflation and undermine the export engine of the eurozone's largest economies just as recovery gains momentum.
With luxury hotels fully booked, affluent Super Bowl attendees are turning to off-market mega-mansions in the Bay Area, driving last-minute rental prices to unprecedented heights of up to half a million dollars for a single week.
Driven by robust subscriber growth, a surge in free cash flow, and a new $10 billion buyback plan, AT&T's stock rallied over 10% this week, signaling renewed investor confidence in the telecom giant's convergence strategy.
The 179-year-old tobacco giant Philip Morris International is closing its Richmond, Virginia office, eliminating 135 positions, as it aggressively restructures around its smoke-free product portfolio, led by the ZYN nicotine pouch brand.
After a relatively subdued 2025, Wall Street's projections for Nvidia's revenue growth remain robust. Analysts are debating whether the chipmaker's current valuation sets the stage for a significant rebound or a period of consolidation.
As the U.S. wine industry grapples with a multi-year slump, iconic tasting rooms are shuttering. The latest casualty is Hall of Fame NFL coach Dick Vermeil's Napa venue, a move reflecting broader shifts in consumer habits and market pressures.
Crude futures retreated sharply on Monday after weekend comments from U.S. President Donald Trump suggested diplomatic engagement with Iran, easing fears of a military confrontation that had recently buoyed markets.
The Northern Ireland Executive has suspended a planned revaluation of hotel business rates, averting significant tax increases for accommodation providers slated for 2026 and providing temporary stability for the region's tourism industry.
From split boxes to crushed pallets, transit damage remains a multi-billion dollar drain on global supply chains. We examine the systemic mismatches between packaging design and the harsh realities of modern logistics.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
Goldcom's (GOLD) shares have soared nearly 90% in the past year, leaving investors to grapple with a critical question: has the market already priced in all the good news, or is there still room to run? A deep dive into the valuation metrics reveals a stark contradiction.
Vital Farms (VITL) is drawing renewed investor attention following a series of earnings estimate upgrades and consistent beats. Despite a recent pullback, analysts see significant upside, citing strong brand positioning and operational scale. However, underlying challenges in retail volumes and cash flow present a more complex picture for the pasture-raised egg producer.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
